- Telomir Pharmaceuticals (NASDAQ:TELO) announced promising preclinical results for Telomir-1, an oral therapeutic for age-related macular degeneration (AMD).
- Study using zebrafish model demonstrated vision restoration, retinal regeneration, and significant reductions in oxidative stress.
- Telomir-1 could offer significant advantages over traditional treatments due to its oral delivery method.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has reported groundbreaking preclinical results for its novel oral therapeutic, Telomir-1, aimed at treating age-related macular degeneration (AMD). In a 14-day study using a genetically modified zebrafish model, Telomir-1 successfully demonstrated vision restoration and retinal regeneration.
The study utilized zebrafish mutants that mimic human AMD pathology, exhibiting progressive retinal degeneration and oxidative stress. Key outcomes showed complete recovery of the inner nuclear layer thickness, improved ganglion cell layer integrity, and a 50% reduction in reactive oxygen species levels. Furthermore, no mortality was observed in the treatment groups, contrasting with a 15% mortality rate in untreated animals.
This development represents a potential paradigm shift in AMD treatment, as Telomir-1 is the first oral drug to show such comprehensive retinal restoration and vision recovery in animal models. The oral administration route offers the potential for easier treatment delivery compared to traditional eye injections.
Although these findings are promising, Telomir-1 remains in the preclinical stage, with human efficacy yet to be proven. The company acknowledges that future clinical trials are necessary to verify the drug's safety and effectiveness in humans.
